SOLIDCURE
ActiveSummary
SOLIDCURE has been active since 2004 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.2m and a net result of €230,715. Equity is growing by ~37.5% per year across the filed fiscal years. Its solvency ranks better than 55% of 143 sector peers (NACE 20, fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
15-05
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
16-01
State Gazette act
Resignation: Bizzway (non-statutory director)Permanent representative: Tim COUCKE · Appointment: AMPIRIUM (non-statutory director)6 facts ▸
State Gazette act
Resignation: Bizzway (non-statutory director)
Permanent representative: Tim COUCKE · Appointment: AMPIRIUM (non-statutory director)6 facts ▸
- General meeting, 10-12-2025
- Director resignation, Bizzway (non-statutory director)
- Permanent representative, Tim COUCKE (permanent representative)
- Other statement, algemene vergadering, kennisname en akkoord ontslag vaste vertegenwoordiger
- Director appointment, AMPIRIUM (non-statutory director)
- Permanent representative, Tim COUCKE (permanent representative)
2025
31-12
Financial
Equity above €1mEq €1.2m ▲24.2%
8 profitable years in a row build equity to €1.2m.
29-10
State Gazette act
Resignation: Epoxon (director)Permanent representative: Scherrens Frank · Appointment: Epoxon (statutory director) · Director discharge12 facts ▸
State Gazette act
Resignation: Epoxon (director)
Permanent representative: Scherrens Frank · Appointment: Epoxon (statutory director) · Director discharge12 facts ▸
- General meeting, 24-10-2025
- Director resignation, Epoxon (director)
- Permanent representative, Scherrens Frank (permanent representative)
- Director discharge, Epoxon
- Director appointment, Epoxon (statutory director)
- Permanent representative, Scherrens Frank (permanent representative)
- Permanent representative, Scherrens Frank (permanent representative)
- Other statement, 1200, tien aandelen voor één aandeel
- Shareholding, 600
- Shareholding, 600
- Capital
- Power of attorney, Niels BOURGOIS
21-02
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Highest result since 2018net €756,578 ▲8.3%
Operating result €818,484, net result €756,578, both a record.
25-06
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
31-12
Financial
Equity above €500,000Eq €796,623 ▲59.9%
6 profitable years in a row build equity to €796,623.
14-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
08-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
02-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-12
Financial
Equity above €200,000Eq €213,451 ▲15%
3 profitable years in a row build equity to €213,451.
Show earlier events
17-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
08-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
27-06
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
31-05
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
2 of 9 acts read
About the unread acts
Of the 9 Belgian State Gazette acts we know for this company, 2 have been read. The other 7 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.